摘要
目的分析不同新辅助化疗方案对三阴性乳腺癌治疗的疗效。方法选择2017年1月至2019年1月来我院治疗的90例三阴性乳腺癌患者,随机分成实验组与常规组,各组45例。实验组应用多西紫杉醇联合表柔比星方案化疗,常规组应用环磷酰胺联合表柔比星加氟尿嘧啶方案化疗。对比两组治疗效果。结果实验组的治疗效果(39/45)86.67%优于常规组(26/45)57.78%(P<0.05)。实验组的IL-6、IL-8、IL-1β、TNF-α值下降幅度远优于常规组(P<0.05)。两组不良反应率对比,无统计学意义(P>0.05)。结论应用多西紫杉醇联合表柔比星新辅助化疗治疗三阴性乳腺癌,可以较好转变患者免疫系统的失衡,疗效良好,不良反应率,值得临床应用推广。
Objective To analyze the curative effect of different neoadjuvant chemotherapy schemes on the treatment of triple negative breast cancer.Methods 90 cases of triple negative breast cancer treated in our hospital from January 2017 to January 2019 were randomly divided into experimental group and conventional group,45 cases in each group.In the experimental group,doxetaxel combined with phenomirubicin was used for chemotherapy.In the conventional group,cyclophosphamide combined with phenomirubicin combined with fluorouracil was used for chemotherapy.To compare the two groups.Results The therapeutic effect of the experimental group(39/45)86.67%was better than that of the conventional group(26/45)57.78%(P<0.05).The IL-6,IL-8,IL-1β,and TNF-αvalues of the experimental group decreased significantly more than those of the conventional group(P<0.05).The adverse reaction rate of the two groups was not statistically significant(P>0.05).Conclusion The application of doxanthol combined with epiphyllloxacin in the treatment of triple negative breast cancer can change the imbalance of the immune system,the effect is good,and the adverse reaction rate is worthy of clinical application.
作者
刘柳
LIU Liu(Department of Blood Oncology,Fuxin Central Hospital,Fuxin 123000,China)
出处
《中国医药指南》
2020年第20期162-163,共2页
Guide of China Medicine
关键词
新辅助化疗方案
三阴性乳腺癌
效果
Neoadjuvant chemotherapy
Triple negative breast cancer
Effect